Results 151 to 160 of about 3,572,912 (194)
Some of the next articles are maybe not open access.
ST-segment elevation myocardial infarction
Current Treatment Options in Cardiovascular Medicine, 2002ST-segment elevation myocardial infarction (MI) is an emergency medical condition. Expediting the steps leading to coronary reperfusion is of critical importance in improving survival after acute MI. After the diagnosis of acute MI is made, patients should be treated with oxygen, aspirin, nitroglycerin, beta-blockers, heparin, and analgesics, barring ...
Yerem, Yeghiazarians, Peter H., Stone
openaire +2 more sources
ST-segment elevation myocardial infarction
2021ST-elevation myocardial infarction (STEMI) is a life-threatening conditioning caused by an abrup occlusion of an epicardial coronary artery. Reperfusion (ideally by primary angioplasty, and if not timely available by systemic fibrinolysis) massively improves survival in STEMI patients.
Borja Ibanez, Stefan James
openaire +1 more source
St Segment Elevation Myocardial Infarction
2010Over 1.2 million patients suffer from new or recurrent ischemic events annually. This includes an estimated 565,000 cases of first and 300,000 cases of recurrent myocardial infarction. Although mortality from acute myocardial infarction (AMI) has declined in recent years, it still remains high at 25–30%. The most common cause of ST elevation AMI (STEMI)
openaire +2 more sources
ST-segment elevation myocardial infarction
2015Acute myocardial infarction with ST-segment elevation is a common and dramatic manifestation of coronary artery disease. It is caused by the rupture of an atherosclerotic plaque in a coronary artery, leading to its total thrombotic occlusion and resultant ischaemia and necrosis of downstream myocardium.
Adrian Cheong +2 more
openaire +1 more source
ST segment elevation not associated with myocardial infarction
2009Case: Michael Moore is a 72-year-old man with a long-standing history of hypertension and diabetes. He came to the office with vague complaints of “I do not feel well” but specifically denies chest pain. His ECG is shown in Figure 1.
openaire +1 more source
Acute Revascularization in ST-Segment-Elevation Myocardial Infarction
Current Atherosclerosis Reports, 2014We briefly and comprehensively present some of the novel findings in the field of revascularization therapy and management of ST-segment-elevation myocardial infarction (STEMI). We highlight the latest evidence-based advancements in the pharmacological and mechanical treatment of patients who presented with STEMI.
Petko, Prodanov, Petr, Widimsky
openaire +2 more sources
Management of non–ST-Segment Elevation Myocardial Infarction
Medical Clinics of North America, 2007Non-ST-segment elevation myocardial infarction (NSTEMI) is a major cause of cardiovascular morbidity and mortality in the United States. It represents the highest risk category of non-ST-segment elevation acute coronary syndromes (NSTEACS), for which timely diagnosis and appropriate therapy are paramount to improve outcomes.
Stephen E, Van Horn, Calin V, Maniu
openaire +2 more sources
Early Management of ST-segment Elevation Myocardial Infarction
Cardiology Clinics, 2006Improvements in the management of ST-segment elevation myocardial infarction(STEMI) have led to a reduction in the acute and long-term mortality rates. The first important decision in the care of patients who have STEMI is the method of reperfusion. Whether percutaneous intervention (PCI) or fibrinolytic therapy is chosen depends on a number of factors.
Amish C, Sura, Mark D, Kelemen
openaire +2 more sources
Contemporary management of ST-segment elevation myocardial infarction
Internal and Emergency Medicine, 2016ST-elevation myocardial infarction (STEMI), which constitutes nearly 25-40 % of current acute myocardial infarction (AMI) cases, is a medical emergency that requires prompt recognition and treatment. Since the 2013 STEMI practice guidelines, a wealth of additional data that may further advance optimal STEMI practices has emerged.
Ajay, Yadlapati +4 more
openaire +2 more sources
Spotlight on Enoxaparin in ST-Segment Elevation Myocardial Infarction†
BioDrugs, 2008Enoxaparin (enoxaparin sodium; Lovenox) is a low-molecular-weight heparin (LMWH) that has recently been approved by the US FDA for use in patients with medically managed ST-segment myocardial infarction (STEMI), or STEMI with subsequent percutaneous coronary intervention.
Natalie J, Carter +2 more
openaire +2 more sources